These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 33246108

  • 21. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
    Dwyer MP, Keertikar K, Paruch K, Alvarez C, Labroli M, Poker C, Fischmann TO, Mayer-Ezell R, Bond R, Wang Y, Azevedo R, Guzi TJ.
    Bioorg Med Chem Lett; 2013 Nov 15; 23(22):6178-82. PubMed ID: 24091081
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors.
    Liang X, Huang Y, Zang J, Gao Q, Wang B, Xu W, Zhang Y.
    Bioorg Med Chem; 2016 Jun 15; 24(12):2660-72. PubMed ID: 27137359
    [Abstract] [Full Text] [Related]

  • 24. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors.
    Wang Y, Wan S, Li Z, Fu Y, Wang G, Zhang J, Wu X.
    Eur J Med Chem; 2018 Jul 15; 155():210-228. PubMed ID: 29886324
    [Abstract] [Full Text] [Related]

  • 25. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P, Dong J, Zhong B, Zhang D, Yuan H, Jin C, Xu X, Li H, Zhou Y, Liang Z, Ji M, Xu T, Song G, Zhang L, Chen G, Meng X, Sun D, Shih J, Zhang R, Hou G, Wang C, Jin Y, Yang Q.
    Bioorg Med Chem Lett; 2016 Apr 15; 26(8):1910-8. PubMed ID: 26979157
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T, Lamb ML, Scott DA, Wang H, Block MH, Lyne PD, Lee JW, Davies AM, Zhang HJ, Zhu Y, Gu F, Han Y, Wang B, Mohr PJ, Kaus RJ, Josey JA, Hoffmann E, Thress K, Macintyre T, Wang H, Omer CA, Yu D.
    J Med Chem; 2008 Aug 14; 51(15):4672-84. PubMed ID: 18646745
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM, El-Gamal MI, Abdel-Maksoud MS, Yoo KH, Baek D, Choi J, Lee H, Oh CH.
    J Enzyme Inhib Med Chem; 2016 Aug 14; 31(sup2):111-122. PubMed ID: 27255180
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH, Mohamed MS, Ragb EA.
    Bioorg Chem; 2019 Jul 14; 88():102929. PubMed ID: 31015179
    [Abstract] [Full Text] [Related]

  • 35. Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors.
    Gilles P, Kashyap RS, Freitas MJ, Ceusters S, Van Asch K, Janssens A, De Jonghe S, Persoons L, Cobbaut M, Daelemans D, Van Lint J, Voet ARD, De Borggraeve WM.
    Eur J Med Chem; 2020 Nov 01; 205():112638. PubMed ID: 32835918
    [Abstract] [Full Text] [Related]

  • 36. Exploring the chemical space around the privileged pyrazolo[3,4-d]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl.
    Vignaroli G, Mencarelli M, Sementa D, Crespan E, Kissova M, Maga G, Schenone S, Radi M, Botta M.
    ACS Comb Sci; 2014 Apr 14; 16(4):168-75. PubMed ID: 24597676
    [Abstract] [Full Text] [Related]

  • 37. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
    Das J, Moquin RV, Pitt S, Zhang R, Shen DR, McIntyre KW, Gillooly K, Doweyko AM, Sack JS, Zhang H, Kiefer SE, Kish K, McKinnon M, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2652-7. PubMed ID: 18359226
    [Abstract] [Full Text] [Related]

  • 38. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N, Pan J, Hao Q, Li Y, Zhou W.
    Bioorg Med Chem; 2018 May 01; 26(8):2165-2172. PubMed ID: 29567295
    [Abstract] [Full Text] [Related]

  • 39. Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.
    Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY.
    Eur J Med Chem; 2021 Apr 15; 216():113265. PubMed ID: 33652352
    [Abstract] [Full Text] [Related]

  • 40. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.
    Chung CY, Li SM, Zeng WZ, Uramaru N, Huang GJ, Juang SH, Wong FF.
    Bioorg Chem; 2024 Jul 15; 148():107424. PubMed ID: 38728908
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.